This application describes one of five proposals being submitted in conjunction with the network application entitled, """"""""The Menopausal Symptoms Initiative -Finding Lasting Answers to Sweats and Hot Flashes (MSI- FLASH)"""""""". Our network and data coordinating center (DCC) will be jointly led by two Co-PIs of the Women's Health Initiative, Clinical Coordinating Center (Seattle) who have worked together for over a decade (LaCroix, Anderson, PIs). The MSI-FLASH network has five clinical sites: Boston, MA (Cohen, Joffe, PIs);Indianapolis, IN (Carpenter, PI);Oakland, CA (Sternfeld, Caan, PIs);Philadelphia, PA (Freeman, PI);and Seattle, WA (Newton, Reed, PIs). This multidisciplinary investigator group proposes five randomized controlled trials testing a range of behavioral, mind-body, hormonal and pharmacologic interventions. Our overall goal is to fulfill the main objective of the RFA, """"""""New Interventions for Menopausal Symptoms (U01)"""""""", to accelerate the identification of effective remedies for vasomotor symptoms (VMS). In this site application we propose a multicenter, factorial design, RCT of yoga, ultra low-dose estradiol (E2) gel and placebo gel to be conducted in Seattle, Indianapolis and Boston. The primary aims are to: 1. Evaluate the effects of yoga vs. no yoga on: a) subjective VMS frequency;and b) VMS bothersomeness;and 2. Evaluate the effects of ultra-low dose estrogen (E2) gel vs. placebo gel on: a) subjective VMS frequency;and b) bothersomeness. Our hypotheses are that 1. The effect of yoga will be greater than no yoga on: a) subjective VMS frequency and b) VMS bothersomeness;and 2. The effect of ultra-low dose E2 gel will be greater than no E2 gel on: a) subjective VMS frequency;and b) bothersomeness. Our secondary aims are: 1. To evaluate the effects of yoga and ultra-low dose E2 gel on other common menopause outcomes including: a) objective VMS frequency (Bahr monitor);b) sleep (PSQI, Actigraph"""""""");and c) mood (CESD, HADS);and 2. To examine whether the combined effect of yoga and ultra low-dose E2 on our primary and secondary outcomes is greater than the effect of either alone. To accomplish our specific aims we will: 1) recruit and randomize 400 women to one of 4 treatment arms for 12 weeks (placebo gel;yoga + placebo gel;ultra low-dose E2 gel;yoga + ultra low-dose E2 gel);2) measure primary and secondary outcomes at baseline and 12 weeks;and 3) compare changes in outcomes in yoga and ultra low-dose E2 gel groups to placebo;and 4) compare changes in primary and secondary outcomes for yoga + ultra low-dose E2 gel to the effects of either intervention alone (if yoga alone is efficacious).

National Institute of Health (NIH)
National Institute on Aging (NIA)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAG1-ZIJ-5 (M2))
Program Officer
Hannah, Judy S
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Group Health Cooperative
United States
Zip Code
Buchanan, Diana Taibi; Landis, Carol A; Hohensee, Chancellor et al. (2016) Effects of Yoga and Aerobic Exercise on Actigraphic Sleep Parameters in Menopausal Women with Hot Flashes. J Clin Sleep Med :
Jones, Salene M W; Guthrie, Katherine A; Reed, Susan D et al. (2016) A yoga & exercise randomized controlled trial for vasomotor symptoms: Effects on heart rate variability. Complement Ther Med 26:66-71
Reed, S D; Newton, K M; Larson, J C et al. (2016) Daily salivary cortisol patterns in midlife women with hot flashes. Clin Endocrinol (Oxf) 84:672-9
Carpenter, Janet S; Jones, Salene M W; Studts, Christina R et al. (2016) Female Sexual Function Index Short Version: A MsFLASH Item Response Analysis. Arch Sex Behav 45:1897-1905
Jones, Salene M W; Guthrie, Katherine A; LaCroix, Andrea Z et al. (2016) Is heart rate variability associated with frequency and intensity of vasomotor symptoms among healthy perimenopausal and postmenopausal women? Clin Auton Res 26:7-13
Carpenter, J S; Woods, N F; Otte, J L et al. (2015) MsFLASH participants' priorities for alleviating menopausal symptoms. Climacteric 18:859-66
Freeman, Ellen W; Ensrud, Kristine E; Larson, Joseph C et al. (2015) Placebo improvement in pharmacologic treatment of menopausal hot flashes: time course, duration, and predictors. Psychosom Med 77:167-75
Caan, Bette; LaCroix, Andrea Z; Joffe, Hadine et al. (2015) Effects of estrogen and venlafaxine on menopause-related quality of life in healthy postmenopausal women with hot flashes: a placebo-controlled randomized trial. Menopause 22:607-15
Otte, Julie L; Rand, Kevin L; Landis, Carol A et al. (2015) Confirmatory factor analysis of the Pittsburgh Sleep Quality Index in women with hot flashes. Menopause 22:1190-6
Guthrie, Katherine A; LaCroix, Andrea Z; Ensrud, Kristine E et al. (2015) Pooled Analysis of Six Pharmacologic and Nonpharmacologic Interventions for Vasomotor Symptoms. Obstet Gynecol 126:413-22

Showing the most recent 10 out of 24 publications